Drug
Oxymorphone clinical trials
Also written Opana.
- studies test it
- 21
- open now
- 0
- in phase 3
- 13
- first study started
- 2001
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2003 | 3 |
| 2004 | 2 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 2 |
| 2013 | 1 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 3
- 13
- Phase 4
- 2
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 3
Endo Pharmaceuticals (13) · Sandoz (2) · Icahn School of Medicine at Mount Sinai (2) · MedVadis Research Corporation (1) · Vanderbilt University (1) · Roxane Laboratories (1) · Endo USA Inc., a Keenova Therapeutics Company (1)
Often tested with
Tested in the same studies.
Propofol (1) · Sevoflurane (1) · Isoflurane (1) · Desflurane (1) · Scopolamine (1) · Droperidol (1) · Haloperidol (1) · Dexamethasone (1)
Studies
Open first, then newest update. How each study uses Oxymorphone is read from its arms, and is right about nine times in ten.
Testing it · 21
- Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant PainCompletedPhase 3Endo PharmaceuticalsNCT00226421Written as Oxymorphone Extended Release
- Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant PainCompletedPhase 3Endo PharmaceuticalsNCT00225797Written as Oxymorphone Extended Release
- Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive FunctioningCompletedPhase 4MedVadis Research CorporationNCT00930943Written as Oxymorphone ER
- Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric SubjectsTerminatedPhase 3Endo PharmaceuticalsNCT02687451Written as Oxymorphone HCl
- Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric SubjectsCompletedPhase 3Endo PharmaceuticalsNCT01210352Written as oxymorphone HCl
- Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced ChildrenSuspendedPhase 3Endo PharmaceuticalsNCT04681027Written as Oxymorphone hydrochloride (HCl)
- Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric SubjectsTerminatedPhase 3Endo PharmaceuticalsNCT00765856Written as Oxymorphone ER
- Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) ProphylaxisCompletedNot applicableVanderbilt UniversityNCT02625181Written as Oxymorphone
- Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.CompletedPhase 3Endo PharmaceuticalsNCT00801398Written as Oxymorphone IR
- Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted ConditionsCompletedPhase 1Roxane LaboratoriesNCT01210638Written as Oxymorphone
- Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)CompletedPhase 4Endo PharmaceuticalsNCT00955110Written as Oxymorphone ER
- Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed ConditionsCompletedPhase 1SandozNCT00857142Written as oxymorphone hydrochloride
- Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted ConditionsCompletedPhase 1SandozNCT00857428Written as oxymorphone
- A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)CompletedNot applicableIcahn School of Medicine at Mount SinaiNCT00580294Written as Oxymorphone
- Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric SubjectsWithdrawnPhase 3Endo PharmaceuticalsNCT01206907Written as oxymorphone IR
- Oxymorphone Extended Release in Patients With Cancer or Neuropathic PainCompletedPhase 3Endo PharmaceuticalsNCT00911261Written as Oxymorphone Extended Release
- Post-operative Efficacy and Safety StudyCompletedPhase 3Endo USA Inc., a Keenova Therapeutics CompanyNCT00904085Written as Oxymorphone IR
- Open Label Assessment of Long-Term Safety and UtilityCompletedPhase 3Endo PharmaceuticalsNCT00904449Written as Oxymorphone ER
- Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic PainCompletedPhase 3Endo PharmaceuticalsNCT00911287Written as Oxymorphone extended release
- A Pilot Study of Ultra Rapid Opioid Rotation and Titration of OxymorphoneStatus unknownNot applicableIcahn School of Medicine at Mount SinaiNCT00945919Written as Oxymorphone ER
See all 21 studies that test Oxymorphone →
Given in every arm · 1 — Oxymorphone is usual care beside what is tested
Codes
What other systems call Oxymorphone · ClinicalTrials.gg INT007942
- MeSH (NLM) D010111OxymorphoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9VXA968E0COXYMORPHONEConfirmed FDA, NLM, Wikidata
- RxNorm 7814Confirmed FDA, Wikidata
- Wikidata Q423380oxymorphoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29314OxymorphoneOne source FDA
- DrugBank DB01192One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D010111 | Oxymorphone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9VXA968E0C | OXYMORPHONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 7814 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423380 | oxymorphone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29314 | Oxymorphone | One source FDA |
| DrugBank | DB01192 | — | One source Wikidata |
Also registered as oxymorphone hydrochloride (UNII 5Y2EI94NBC · RxNorm 82064).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.